Trial Profile
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Atropine; Glycopyrrolate; Neostigmine
- Indications Neuromuscular blockade
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 05 Oct 2020 Primary endpoint has been met. (Time to Recovery of Participant Train-Of-Four (TOF) Ratio to 0.9 [Part B])
- 05 Oct 2020 Results presented at the ANESTHESIOLOGY 2020 Annual Meeting of the American Society of Anesthesiologists
- 11 Feb 2020 Status changed from recruiting to completed.